ZIOPHARM Oncology Inc - Stock Price History | ZIOP

Historical daily share price chart and data for ZIOPHARM Oncology Inc since 2021 adjusted for splits. The latest closing stock price for ZIOPHARM Oncology Inc as of September 27, 2021 is 2.12.
  • The all-time high ZIOPHARM Oncology Inc stock closing price was 640.00 on August 24, 2005.
  • The ZIOPHARM Oncology Inc 52-week high stock price is 5.95, which is 180.7% above the current share price.
  • The ZIOPHARM Oncology Inc 52-week low stock price is 1.26, which is 40.6% below the current share price.
  • The average ZIOPHARM Oncology Inc stock price for the last 52 weeks is 2.98.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ZIOPHARM Oncology Inc Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 3.0010 4.6200 4.9800 1.9000 2.5200 -46.61%
2019 4.3289 2.2100 6.9400 2.0000 4.7200 152.41%
2018 3.4666 4.4400 5.1400 1.6100 1.8700 -54.83%
2017 5.8622 5.4700 7.5100 4.0000 4.1400 -22.62%
2016 6.3580 7.9700 9.5900 4.4900 5.3500 -35.62%
2015 10.5733 5.1300 14.5700 4.9600 8.3100 63.91%
2014 3.7240 4.2000 5.4200 2.4300 5.0700 16.82%
2013 3.2947 4.5300 5.7100 1.5200 4.3400 4.33%
2012 5.0602 4.3000 6.2200 3.9900 4.1600 -5.67%
2011 5.5125 4.7900 7.7000 3.8500 4.4100 -5.36%
2010 4.1756 2.9500 6.0900 2.9100 4.6600 57.43%
2009 1.7123 0.6000 3.9560 0.5100 2.9600 410.34%
2008 2.0597 3.4800 3.5800 0.5700 0.5800 -83.62%
2007 4.3934 5.9700 5.9700 2.2200 3.5400 -40.70%
2006 5.0848 3.6000 6.5000 3.6000 5.9700 83.69%
2005 18.1867 640.0000 640.0000 3.2500 3.2500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.457B $0.000B
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29